Androgen News and Research

RSS

Bellicum Pharmaceuticals starts phase I/II trial of novel advanced prostate cancer vaccine

Bellicum Pharmaceuticals, Inc. today announced dosing of the first patient in a Phase I/II clinical trial of BP-GMAX-CD1, a novel pharmacologically regulated dendritic cell vaccine for the treatment of prostate cancer. The disease-specific trial is being conducted under a Bellicum Investigational New Drug application allowed by the FDA in 2008. The company anticipates reporting initial results of the study in 2010.

6 Aug 2009

Study finds few patients die from prostate cancer within 15 years of radical prostatectomy

Investigators at Memorial Sloan-Kettering Cancer Center (MSKCC), along with collaborating teams at the Cleveland Clinic and the University of Michigan, have completed the first large- scale, multi-institutional study of prostate cancer death after standard treatment to remove the prostate since PSA screening has become widely used as a method to screen for the disease.

28 Jul 2009

Discovery of key event in prostate cancer progression

A study led by researchers at the Ohio State University Comprehensive Cancer Center and Dana-Farber Cancer Institute reveals how late-stage, hormone-independent prostate tumors gain the ability to grow without need of hormones.

24 Jul 2009

Protein produced by gene fusion that may also be targeted for new prostate cancer therapies

Researchers from NewYork-Presbyterian Hospital/Weill Cornell Medical Center have discovered a new gene fusion that is highly expressed in a subset of prostate cancers.

24 Jul 2009

Antisense Therapeutics trial of ATL1101 in prostate cancer shows promise

Antisense Therapeutics Ltd. (ASX: ANP) has reported further positive results from its collaborative preclinical research studies on the therapeutic potential of ATL1101 in prostate cancer. In experimental models, ATL1101 treatment significantly enhanced the tumor-suppressive effect of the cancer drug Paclitaxel. Paclitaxel is one of a class of drugs known as taxanes.

18 Jun 2009

Hormone therapy may confer more aggressive properties to prostate tumours

Hormone therapy is often given to patients with advanced prostate cancer. While it is true that the treatment prevents growth of the tumour, it also changes its properties. Some of these changes may result in the tumour becoming more aggressive and more liable to form metastases. This is one of the conclusion of a thesis presented at the Sahlgrenska Academy, University of Gothenburg, Sweden.

10 Jun 2009

High levels of estradiol hormone in men with heart failure linked to increased risk of death

Men with systolic chronic heart failure who have low or high levels of estradiol, a form of the hormone estrogen, have an increased risk of death compared with men with moderate levels of this hormone, according to a study in the May 13 issue of JAMA, the Journal of the American Medical Association.

12 May 2009

Injectable androgen preparation may provide effective male contraception

Researchers in China may have found a method for male contraception that is effective, reversible and without serious short-term adverse effects according to a new study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM).

4 May 2009

Experimental immunotherapy significantly prolongs survival in men with advanced prostate cancer

Sipuleucel-T (Provenge), an experimental immunotherapy improved survival in men with metastatic disease, according to new results to be presented April 28 at the American Urological Association (AUA) Annual Scientific Meeting in Chicago.

29 Apr 2009

$Prostate cancer therapy increases risk of fractures and cardiovascular-related death$

Prostate cancer therapy increases risk of fractures and cardiovascular-related death

Prostate cancer patients who undergo therapy to decrease testosterone levels increase their risk of developing bone- and heart-related side effects compared to patients who do not take these medications, according to a new analysis.

27 Apr 2009

Ferring Pharmaceuticals launches new trial of Degarelix for intermittent androgen deprivation therapy

Ferring Pharmaceuticals has announced the launch of a Phase IIIB clinical trial of degarelix for injection, a new injectable gonadotropin-releasing hormone (GnRH) receptor antagonist approved by the U.S. Food and Drug Administration (FDA) for the treatment of hormone sensitive advanced prostate cancer.

27 Apr 2009

AUA counters mainstream recommendations with new best practice statement on PSA testing

The American Urological Association (AUA) today issued new clinical guidance - which directly contrasts recent recommendations issued by other major groups - about prostate cancer screening, asserting that the prostate-specific antigen (PSA) test should be offered to well-informed, men aged 40 years or older who have a life expectancy of at least 10 years.

27 Apr 2009

New therapy for metastatic prostate cancer shows promise

A new therapy for metastatic prostate cancer has shown considerable promise in early clinical trials involving patients whose disease has become resistant to current drugs.

12 Apr 2009

Gene fusion discovery may lead to improved prostate cancer test

A newly discovered gene fusion is highly expressed in a subset of prostate cancers, according to a study by researchers at Weill Cornell Medical College.

12 Apr 2009

Clinical trials for two compounds show promise in advanced prostate cancer

In a paper published online this week in Science Express (the online version of Science magazine), researchers report that early clinical trials for two compounds, MDV3100 and RD162, show initial promise for patients suffering from an advanced metastatic form of the disease known as castration-resistant prostate cancer.

9 Apr 2009

Experimental drug lowers PSA levels

A new multi-center study shows that an experimental drug lowers prostate specific antigen (PSA) levels – a marker for tumor growth – in men with advanced prostate cancer for whom traditional treatment options have failed.

9 Apr 2009

New therapy for metastatic prostate cancer shows promise

A new therapy for metastatic prostate cancer has shown considerable promise in early clinical trials involving patients whose disease has become resistant to current drugs.

8 Apr 2009

$New target for treatment of hormone refractory prostate cancer$

Androgen News and Research

Bellicum Pharmaceuticals starts phase I/II trial of novel advanced prostate cancer vaccine

Study finds few patients die from prostate cancer within 15 years of radical prostatectomy

Discovery of key event in prostate cancer progression

Protein produced by gene fusion that may also be targeted for new prostate cancer therapies

Antisense Therapeutics trial of ATL1101 in prostate cancer shows promise

Hormone therapy may confer more aggressive properties to prostate tumours

High levels of estradiol hormone in men with heart failure linked to increased risk of death

Injectable androgen preparation may provide effective male contraception

Experimental immunotherapy significantly prolongs survival in men with advanced prostate cancer

Prostate cancer therapy increases risk of fractures and cardiovascular-related death

Ferring Pharmaceuticals launches new trial of Degarelix for intermittent androgen deprivation therapy

AUA counters mainstream recommendations with new best practice statement on PSA testing

New therapy for metastatic prostate cancer shows promise

Gene fusion discovery may lead to improved prostate cancer test

Clinical trials for two compounds show promise in advanced prostate cancer

Experimental drug lowers PSA levels

New therapy for metastatic prostate cancer shows promise

New target for treatment of hormone refractory prostate cancer

New therapeutic approaches to castrate resistant prostate cancer

Testosterone doping tests in sport ignore ethnic differences in hormone activity

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News